ABSTRACT
The limit of detection (LOD) of rifampicin heteroresistance for phenotypic drug susceptibility 28 testing by the proportion method is 1%, yet is insufficiently documented for RDTs. We 29 therefore aimed to determine, for the four RDTs (XpertMTB/RIF, XpertMTB/RIF Ultra,
30
GenoTypeMTBDRplusv2.0, and GenoscholarNTM+MDRTBII), the LOD per probe and 31 mutation, validated by colony-forming-unit-counting and targeted deep sequencing 32 (Deeplex-MycTB). 33 We selected one rifampicin-susceptible and four rifampicin-resistant strains, with mutation 34 D435V, H445D, H445Y, and S450L respectively, mixed them in various proportions in 35 triplicate, tested them with each RDT, and determined the LODs per mutation type. MycTB revealed concordant proportions of the minority resistant variants in the mixtures.
37
The Deeplex-MycTB-validated-LODs ranged from 20-80% for XpertMTB/RIF, 20-70% for 38 Xpert Ultra, 5-10% for GenoTypeMTBDRplusv2.0, and 1-10% for GenoscholarNTM+MTBII for 39 the different mutations. 40 Deeplex-MycTB, GenoTypeMTBDRplusv2.0, and GenoscholarNTM+MDRTBII, provide explicit 41 information on rifampicin heteroresistance for the most frequently detected mutations. 42 Classic Xpert and Ultra report rifampicin heteroresistance as rifampicin resistance, while 43 Ultra may denote rifampicin heteroresistance through 'mixed patterns' of wild-type and 44 mutant melt probe melt peak temperatures. 45 Overall, our findings inform end-users that the threshold for reporting resistance in case of 46 rifampicin heteroresistance is the highest for Classic Xpert and Ultra, to resolve phenotypic 47 and genotypic discordant rifampicin-resistant TB results. In this study, we define RIF heteroresistance limit of detection (LOD) as the minimum 68 proportion of mutant bacilli in a total mycobacterial population present in a sample, needed 69 for RIF resistance to be detected (4). It is known that phenotypic drug susceptibility testing 70 by the proportion method determines at least 1% resistant subpopulation in clinical samples 71 (4, 13, 14) . In the abovementioned RDTs however, the RIF heteroresistance LOD in 72 association with the specific rpoB mutation, is insufficiently documented. Thermolysates of the RR:RS mixtures prepared as previously described (26) Figure S2 ).
178
We excluded replicate 3 from the first batch of S450L-WT preparation due to substantially at least 70-80% mutant bacilli (Table S2) Apart from the slight differences in the LODs recorded for classic Xpert and Ultra, we Tables   483   Table 1 . Proportions of minority resistant variants detected among the rifampicin- 
